The role of pharmacoeconomic information from the pharmaceutical industry perspective

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The purpose of this study was to determine the factors that pharmaceutical industry representatives believe are important in the drug benefit decisions of MCOs. Respondents indicated that a drug's clinical features and acquisition cost were the most important factors in making drug-coverage decisions. Ninety percent of respondents indicated that they provide some type of pharmacoeconomic data on either some or almost every visit with their customers. Twenty (95%) of 21 respondents thought that current pharmacoeconomic information was helpful to MCOs in making drug benefit decisions. However, 80% thought important barriers existed to using health outcome and pharmacoeconomic data.

Original languageEnglish (US)
Pages (from-to)39-45
Number of pages7
JournalDrug Benefit Trends
Volume13
Issue number3
StatePublished - 2001

Fingerprint

Pharmaceutical Economics
Drug Industry
Pharmaceutical Preparations
Costs and Cost Analysis
Health
Surveys and Questionnaires
MCO

Keywords

  • MCOs
  • Pharmaceutical industry
  • Pharmacoeconomics

ASJC Scopus subject areas

  • Leadership and Management
  • Pharmaceutical Science

Cite this

The role of pharmacoeconomic information from the pharmaceutical industry perspective. / Armstrong, Edward P; Abarca, J.; Jones-Grizzle, Amy J.

In: Drug Benefit Trends, Vol. 13, No. 3, 2001, p. 39-45.

Research output: Contribution to journalArticle

@article{bd4f98033f9f415e9bf0b8d28c16a565,
title = "The role of pharmacoeconomic information from the pharmaceutical industry perspective",
abstract = "The purpose of this study was to determine the factors that pharmaceutical industry representatives believe are important in the drug benefit decisions of MCOs. Respondents indicated that a drug's clinical features and acquisition cost were the most important factors in making drug-coverage decisions. Ninety percent of respondents indicated that they provide some type of pharmacoeconomic data on either some or almost every visit with their customers. Twenty (95{\%}) of 21 respondents thought that current pharmacoeconomic information was helpful to MCOs in making drug benefit decisions. However, 80{\%} thought important barriers existed to using health outcome and pharmacoeconomic data.",
keywords = "MCOs, Pharmaceutical industry, Pharmacoeconomics",
author = "Armstrong, {Edward P} and J. Abarca and Jones-Grizzle, {Amy J}",
year = "2001",
language = "English (US)",
volume = "13",
pages = "39--45",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "3",

}

TY - JOUR

T1 - The role of pharmacoeconomic information from the pharmaceutical industry perspective

AU - Armstrong, Edward P

AU - Abarca, J.

AU - Jones-Grizzle, Amy J

PY - 2001

Y1 - 2001

N2 - The purpose of this study was to determine the factors that pharmaceutical industry representatives believe are important in the drug benefit decisions of MCOs. Respondents indicated that a drug's clinical features and acquisition cost were the most important factors in making drug-coverage decisions. Ninety percent of respondents indicated that they provide some type of pharmacoeconomic data on either some or almost every visit with their customers. Twenty (95%) of 21 respondents thought that current pharmacoeconomic information was helpful to MCOs in making drug benefit decisions. However, 80% thought important barriers existed to using health outcome and pharmacoeconomic data.

AB - The purpose of this study was to determine the factors that pharmaceutical industry representatives believe are important in the drug benefit decisions of MCOs. Respondents indicated that a drug's clinical features and acquisition cost were the most important factors in making drug-coverage decisions. Ninety percent of respondents indicated that they provide some type of pharmacoeconomic data on either some or almost every visit with their customers. Twenty (95%) of 21 respondents thought that current pharmacoeconomic information was helpful to MCOs in making drug benefit decisions. However, 80% thought important barriers existed to using health outcome and pharmacoeconomic data.

KW - MCOs

KW - Pharmaceutical industry

KW - Pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=0035061685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035061685&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0035061685

VL - 13

SP - 39

EP - 45

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - 3

ER -